Chronic myeloid leukemia

Sep 29, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·José A Martínez-ClimentFelipe Prosper

Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.

Feb 22, 2008·International Journal of Hematology·Ying WangZhengzheng Fu

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.

May 19, 2009·International Journal of Hematology·Arinobu TojoTomoki Naoe

Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.

Feb 1, 2011·International Journal of Hematology·Masaya OkadaHiroyasu Ogawa

Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models

Dec 23, 2011·International Journal of Hematology·Noriko DokiToshio Kitamura

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.

Jan 21, 2012·International Journal of Hematology·Hidehiro ItonagaYasushi Miyazaki

Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.

Sep 11, 2012·International Journal of Hematology·Zaher K OtrockMiguel R Abboud

Aberrant microRNA expression and its implications in the pathogenesis of leukemias.

Sep 8, 2012·Cellular Oncology (Dordrecht)·Sadegh BabashahMasoud Soleimani

Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia

Jan 24, 2006·Blood Reviews·Timothy Hughes, Susan Branford

Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening

Oct 14, 2003·Bioorganic & Medicinal Chemistry Letters·Hui PengChunzheng Yang

Regulation of neuronal morphogenesis and synaptic function by Abl family kinases

Nov 25, 2003·Current Opinion in Neurobiology·Eva M Y Moresco, Anthony J Koleske

Chronic myeloid leukemia-still a few questions

Jan 17, 2004·Experimental Hematology·John M Goldman

A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction

Mar 25, 2004·Journal of Theoretical Biology·Helen Moore, Natasha K Li

Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era

Mar 24, 2004·Leukemia Research·Richard A Van Etten

Molecular mechanisms of resistance of leukemia to imatinib mesylate

Mar 24, 2004·Leukemia Research·Tetsuzo Tauchi, Kazuma Ohyashiki

Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia

May 4, 2004·Leukemia Research·Antonieta Chávez-GonzálezHector Mayani

The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line

Jun 2, 2005·Leukemia Research·Daniella Yeheskely-HayonEldad J Dann

TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome

Oct 16, 2001·Mutation Research·Y MaruM Shibuya

White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice

May 3, 2000·Lancet·A K Stewart, A C Schuh

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

Feb 22, 2005·Lancet·M BocchiaF Lauria

Clinical significance of reverse BCR/ABL gene rearrangement in Ph-negative chronic myelogenous leukemia

Jun 27, 2000·Leukemia Research·R S Verma, P Chandra

Bcr-Abl variants: biological and clinical aspects

Aug 23, 2002·Leukemia Research·Anjali S Advani, Ann Marie Pendergast

Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome

Jun 14, 2003·Leukemia Research·David P SteensmaChin-Yang Li

Flow cytometric analysis of aneuploidy and S-phase fraction in chronic myeloid leukemia patients: role in early detection of accelerated phase

Jul 16, 2003·Leukemia Research·Anil K TripathiBabu L Tekwani

❮ Previous

Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.